Member Info for LesBoy

Not ours.

UK's antibody testing fiasco exposed: Study shows PHE's coronavirus test misses up to a THIRD of positive results, the Department of Health has cancelled orders worth £70MILLION and a firm given £1m by officials produced a sub-standard test:

https://www.dailymail.co.uk/news/article-8326429/UKs-antibody-testing-fiasco-exposed-PHE-test-misses-cases.html

Not ours.

UK's antibody testing fiasco exposed: Study shows PHE's coronavirus test misses up to a THIRD of positive results, the Department of Health has cancelled orders worth £70MILLION and a firm given £1m by officials produced a sub-standard test:

https://www.dailymail.co.uk/news/article-8326429/UKs-antibody-testing-fiasco-exposed-PHE-test-misses-cases.html

... this is a Solgod forum, FFS.

Abbey Joseph Cohen, a prominent analyst at New York headquartered Goldman Sachs says first past the post shouldn’t mean the race ends.
She argued multiple vaccines would be needed to help the world get out of this pandemic.
“The physicians and scientists with whom I have the opportunity to speak do believe that there are probably seven or eight or more that look promising right now,” Cohen said.
“They think it’s going to take multiple vaccines in order to have enough to actually make dosages available to enough people.”
https://stockhead.com.au/news/goldman-sachs-weighs-in-on-the-vaccine-debate-says-multiple-winners-needed/?utm_medium=email&utm_campaign=Lunchtime%20ASX%20Small%20Cap%20Wrap%20Friday%20May%2015&utm_content=Lunchtime%20ASX%20Small%20Cap%20Wrap%20Friday%20May%2015+CID_6b43d1a1389f2a729967ee34972a79cb&utm_source=Campaign%20Monitor&utm_term=Goldman%20Sachs%20weighs%20in%20on%20the%20vaccine%20debate%20says%20multiple%20winners%20needed

Abbey Joseph Cohen, a prominent analyst at New York headquartered Goldman Sachs says first past the post shouldn’t mean the race ends.
She argued multiple vaccines would be needed to help the world get out of this pandemic.
“The physicians and scientists with whom I have the opportunity to speak do believe that there are probably seven or eight or more that look promising right now,” Cohen said.
“They think it’s going to take multiple vaccines in order to have enough to actually make dosages available to enough people.”
https://stockhead.com.au/news/goldman-sachs-weighs-in-on-the-vaccine-debate-says-multiple-winners-needed/?utm_medium=email&utm_campaign=Lunchtime%20ASX%20Small%20Cap%20Wrap%20Friday%20May%2015&utm_content=Lunchtime%20ASX%20Small%20Cap%20Wrap%20Friday%20May%2015+CID_6b43d1a1389f2a729967ee34972a79cb&utm_source=Campaign%20Monitor&utm_term=Goldman%20Sachs%20weighs%20in%20on%20the%20vaccine%20debate%20says%20multiple%20winners%20needed

Abbey Joseph Cohen, a prominent analyst at New York headquartered Goldman Sachs says first past the post shouldn’t mean the race ends.
She argued multiple vaccines would be needed to help the world get out of this pandemic.
“The physicians and scientists with whom I have the opportunity to speak do believe that there are probably seven or eight or more that look promising right now,” Cohen said.
“They think it’s going to take multiple vaccines in order to have enough to actually make dosages available to enough people.”
https://stockhead.com.au/news/goldman-sachs-weighs-in-on-the-vaccine-debate-says-multiple-winners-needed/?utm_medium=email&utm_campaign=Lunchtime%20ASX%20Small%20Cap%20Wrap%20Friday%20May%2015&utm_content=Lunchtime%20ASX%20Small%20Cap%20Wrap%20Friday%20May%2015+CID_6b43d1a1389f2a729967ee34972a79cb&utm_source=Campaign%20Monitor&utm_term=Goldman%20Sachs%20weighs%20in%20on%20the%20vaccine%20debate%20says%20multiple%20winners%20needed

Abbey Joseph Cohen, a prominent analyst at New York headquartered Goldman Sachs says first past the post shouldn’t mean the race ends.
She argued multiple vaccines would be needed to help the world get out of this pandemic.
“The physicians and scientists with whom I have the opportunity to speak do believe that there are probably seven or eight or more that look promising right now,” Cohen said.
“They think it’s going to take multiple vaccines in order to have enough to actually make dosages available to enough people.”
https://stockhead.com.au/news/goldman-sachs-weighs-in-on-the-vaccine-debate-says-multiple-winners-needed/?utm_medium=email&utm_campaign=Lunchtime%20ASX%20Small%20Cap%20Wrap%20Friday%20May%2015&utm_content=Lunchtime%20ASX%20Small%20Cap%20Wrap%20Friday%20May%2015+CID_6b43d1a1389f2a729967ee34972a79cb&utm_source=Campaign%20Monitor&utm_term=Goldman%20Sachs%20weighs%20in%20on%20the%20vaccine%20debate%20says%20multiple%20winners%20needed

Abbey Joseph Cohen, a prominent analyst at New York headquartered Goldman Sachs says first past the post shouldn’t mean the race ends.
She argued multiple vaccines would be needed to help the world get out of this pandemic.
“The physicians and scientists with whom I have the opportunity to speak do believe that there are probably seven or eight or more that look promising right now,” Cohen said.
“They think it’s going to take multiple vaccines in order to have enough to actually make dosages available to enough people.”
https://stockhead.com.au/news/goldman-sachs-weighs-in-on-the-vaccine-debate-says-multiple-winners-needed/?utm_medium=email&utm_campaign=Lunchtime%20ASX%20Small%20Cap%20Wrap%20Friday%20May%2015&utm_content=Lunchtime%20ASX%20Small%20Cap%20Wrap%20Friday%20May%2015+CID_6b43d1a1389f2a729967ee34972a79cb&utm_source=Campaign%20Monitor&utm_term=Goldman%20Sachs%20weighs%20in%20on%20the%20vaccine%20debate%20says%20multiple%20winners%20needed

Hannam & Partners has set a price target for Greatland Gold PLC of 12.9p, implying 47% upside from the current share price.

The share price valuation derives in part from a calculation of the net present value of Greatland’s Havieron gold project in the Paterson region of Western Australia.

Hannam sets the value of Havieron at a preliminary US$1.67bn, and estimates that Greatland’s share of the development costs is likely to amount to US$33.9mln.

“The significance of Havieron became apparent in November 2018, when an intercept of 275 metres at 4.8 grams per tonne gold and 0.6% copper was released to the market,” writes Hannam’s analyst Andrei Kroupnik.

https://www.proactiveinvestors.co.uk/companies/news/919587/greatland-gold-valued-at-129p-by-hannam--partners-based-on-a-us167bn-valuation-for-havieron-919587.html

Upcoming bank holidays in England and Wales, 2020:
8 May Friday Early May bank holiday (VE day)
25 May Monday Spring bank holiday
31 August Monday Summer bank holiday
25 December Friday Christmas Day
28 December Monday Boxing Day (substitute day)

This is all I could find:

We have watched this company for a while, but it seems that no-one else has been. And we know that there are all sorts of reasons why investors and traders might want to ignore this stock. However we see two catalysts that could see the shares absolutely skyrocket within six months. Yes: this really could be a ten bagger or more by October, probably well before!

One is a potential sale of a non-core asset that could easily bring in cash equivalent of a large part or all of the current market cap.

And the other catalyst is the major part of the business starting to generate cash. Lots of it. In fact it could be generating up to a third of the current market cap PER MONTH!

And that is why the shares are set to roof it!

From Monday Novacyt will supply 288,000 diagnostic tests per week for use in the NHS for an initial six months. There is an option to extend the agreement.

The company is already supplying more than 20 hospitals with its tests after earlier orders from Public Health England.

Novacyt’s Primerdesign subsidiary is developing the test in Southampton. This month the test became the second to be listed by the World Health Organisation as eligible for emergency use, after one produced by Roche, the Swiss multinational.

It expects to double production over the next three months to about eight million tests a month.

https://www.thetimes.co.uk/edition/business/novacyt-boosts-covid-19-testing-in-nhs-deal-3w7bzr5m9

Excellent advice from BBN.

No worries ... best of luck today!

https://www.investegate.co.uk/avacta-group-plc--avct-/rns/notice-of-results---update/202004170700059516J/

Sincere thanks silver51 for your timely updates and sound advice; vrey much appreciated.

More and more independent researchers are considering that the virus causing COVID-19 may ultimately become seasonal. Dr. William Schaffner, an expert in infectious diseases, revealed the following in a statement to Healthline, “We think this coronavirus will likely become more prominent during winter in the Southern Hemisphere… and cycle back to the Northern Hemisphere in the next winter season. We’ll be dealing then with influenza, other respiratory viruses, and the coronavirus.”
The question is: Is this even possible? Could a new virus just show up and become a new seasonal burden we have to fight? The answer is, tragically, ‘yes’, and historians believe this has happened before with a more familiar virus - influenza. The first recordings of the flu date back to 1580.

https://www.ba-bamail.com/content.aspx?emailid=35521

More and more independent researchers are considering that the virus causing COVID-19 may ultimately become seasonal. Dr. William Schaffner, an expert in infectious diseases, revealed the following in a statement to Healthline, “We think this coronavirus will likely become more prominent during winter in the Southern Hemisphere… and cycle back to the Northern Hemisphere in the next winter season. We’ll be dealing then with influenza, other respiratory viruses, and the coronavirus.”
The question is: Is this even possible? Could a new virus just show up and become a new seasonal burden we have to fight? The answer is, tragically, ‘yes’, and historians believe this has happened before with a more familiar virus - influenza. The first recordings of the flu date back to 1580.

https://www.ba-bamail.com/content.aspx?emailid=35521

Thanks to Moneymunch, KnightRider1, TC101, scott1690, dusterhater and Stocksbofs2 for all the information; much appreciated.

This is what I was referring to:

New York/London, 13 January 2020 - Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS), a biotechnology company focusing on the discovery and development of innovative therapeutics for inflammation and oncology indications, announces that it has appointed advisers in relation to an intended redomicile of the Company to Bermuda which is anticipated to occur by Q2-2020, as a consequence of the redomicile the Company will not be seeking to re-admit its ordinary shares on AIM and will therefore seek shareholder consent for its shares to be cancelled from AIM when the redomicile occurs.
A further announcement will be made in due course.

Furthermore, the Company intends to cancel its ADR program and have its Bermuda common shares listed on Nasdaq.

I've searched for the "further announcement", but can't find one .
Hopefully they've changed their mind.